Skip to Content
Merck
  • Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells.

Effects of antithrombotic drugs fondaparinux and tinzaparin on in vitro proliferation and osteogenic and chondrogenic differentiation of bone-derived mesenchymal stem cells.

Journal of orthopaedic research : official publication of the Orthopaedic Research Society (2011-03-25)
Argiris Papathanasopoulos, Dimitrios Kouroupis, Karen Henshaw, Dennis McGonagle, Elena A Jones, Peter V Giannoudis
ABSTRACT

An unexpected side effect of some classes of anticoagulants has been osteoporosis which may be, at least in part, related to deranged mesenchymal stem cell (MSC) function. The aim of the present study was to compare the effect of fondaparinux (FDP), a novel antithrombotic with a traditional widely used low molecular weight heparin, tinzaparin (TZP) on MSC proliferation and differentiation. MSCs were isolated from trabecular bone of 14 trauma patients by a collagenase-based digestion procedure and expanded in standard conditions until passage 3. Proliferation and differentiation of MSCs to chondrocytes and osteoblasts was assessed with or without the addition of FDP and TZP using standard in vitro assays and a broad range of drug concentrations. Flow cytometry was used for MSC phenotyping. In the age studied group (17-74 years old) the MSC frequency in collagenase-released fractions was 641/10(6) cells (range 110-2,158) and their growth characteristics were ∼4 days/population doubling. Cultures had a standard MSC phenotype (CD73+, CD105+, CD146+, CD106+, and CD166+). Cell proliferation was assessed by both colony-forming unit-fibroblast (CFU-F) and colorimetric tetrazolium salt XTT assays. In both assays, MSC proliferation was inhibited by the addition of TZP, particularly at high concentrations. In contrast, FDP had no effect on MSC proliferation. Osteogenic differentiation and chondrogenic differentiation were not affected by the addition of either TZP or FDP. Whilst MSC proliferation, but not differentiation, is negatively affected by TZP, there was no evidence for adverse effects of FDP in this in vitro model system which argues well for its use in the orthopedic setting.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Propidium iodide, ≥94% (HPLC)
Sigma-Aldrich
Trypan Blue, ≥80% (HPLC), Dye content 60 %
Sigma-Aldrich
Toluidine Blue O, certified by the Biological Stain Commission
Sigma-Aldrich
Propidium iodide, ≥94.0% (HPLC)
Sigma-Aldrich
Fast Blue RR Salt, crystalline
Sigma-Aldrich
Trypan Blue, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Toluidine Blue O, Technical grade
Sigma-Aldrich
Crystal Violet, indicator for the determination of the redox potential, S. No.: 785
Sigma-Aldrich
Toluidine Blue, 8.74% (ZN (THEORY)), for microscopy (Hist., Vit.)
Sigma-Aldrich
Crystal Violet, certified by the Biological Stain Commission
Sigma-Aldrich
Crystal Violet, for microscopy (Bact., Bot., Hist., Vit.), indicator (pH 0.1-2.0)
Supelco
Phosphorus standard solution, 0.65 mM (phosphorous)
Sigma-Aldrich
Crystal Violet, ACS reagent, ≥90.0% anhydrous basis
Supelco
Crystal Violet, VETRANAL®, analytical standard